Genmab’s Rinatabart Sesutecan Continues Success in Advanced Ovarian Cancer Clinical Trials
New data from the Phase II RAINFOL-01 study shows rinatabart sesutecan (Rina-S), an investigative antibody-drug conjugate, demonstrated a confirmed objective response rate of 55.6%.
Genmab has shared positive results from the Phase I/II RAINFOL-01 clinical trial showing that its rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug conjugate (ADC), achieved an overall response rate (ORR) of 55.6% in heavily pre-treated ovarian cancer (OC) patients regardless of FRα expression levels. Additionally, 1 out of 10 patients experienced disease progression and the median duration of response (mDOR) was not reached.1
These emerging results are from the B1 cohort of the trial, which is a dose expansion study in patients with histologically or cytologically confirmed advanced OC (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Participants received Rina-S 120 mg/m2 every 3 weeks with a median on-study follow-up of 48 weeks. In addition to the 55.6% ORR, the investigational ADC demonstrated a disease control rate (DCR) of 88.9%.
In the Rina-S 100 mg/m2 every 3 weeks arm, with a median on study follow-up of 46 weeks, the confirmed ORR was 22.7%, the DCR was 86.4%, and the mDOR was not reached.
In a press release, Elizabeth Lee, MD, a medical oncologist in the gynecologic oncology program at Dana-Farber, said, “The antitumor activity observed in the dose expansion cohort continues to demonstrate the potential for a much-needed treatment option for patients with PROC, who have historically had poor prognosis. I am hopeful that further exploration of Rina-S will lead to advancements in the treatment landscape.”
Judith Klimovsky, MD, executive vice president and chief development officer of Genmab, added, “The updated results reinforce the potential of Rina-S and further validate our development approach in advanced ovarian cancer. We are excited to keep moving forward with the ongoing Phase III trial, to evaluate the potential of Rina-S as a treatment option for patients facing this challenging disease.”
This most recent update from Genmab follows encouraging results of Rina-S announced in September 2024. Initially, the ADC demonstrated a confirmed ORR 50% in OC patients treated with Rina-S at the 120 mg/m2 dose once every 3 weeks.2
In a press release from the time, Lee said, “Ovarian cancer presents a significant challenge, especially for those with advanced or recurrent cases, where treatment options and prognosis are often limited. The encouraging Phase I/II data for Rina-S demonstrates the potential for future treatment options for patients. We are looking forward to additional data from tumor-specific dose expansion cohorts.”
According to Genmab, the Phase II RAINFOL-01 and Phase III RAINFOL-02 studies evaluating Rina-S at 120 mg/m2 in patients with platinum resistant ovarian cancer are actively recruiting.
References
1. Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer. News release. Genmab. March 17, 2025. Accessed March 17, 2025. https://www.businesswire.com/news/home/20250317671140/en/Investigational-Rinatabart-Sesutecan-Rina-S-Continues-to-Show-Encouraging-Antitumor-Activity-in-Patients-with-Advanced-Ovarian-Cancer
2. Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial. News release. Genmab. September 15, 2024. Accessed March 17, 2024. https://www.businesswire.com/news/home/20240913038747/en/Investigational-Rinatabart-Sesutecan-Rina-S-Shows-Promising-Anti-Tumor-Activity-as-Single-Agent-in-Heavily-Pretreated-Patients-with-Ovarian-and-Endometrial-Cancers-in-Phase-12-Clinical-Trial
MIRASOL Trial Shows Elahere Significantly Improves Survival in Platinum-Resistant Ovarian Cancer
March 17th 2025In the Phase III MIRASOL trial, Elahere (mirvetuximab soravtansine-gynx) significantly improved progression-free survival and overall survival compared to chemotherapy in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Finds Baricitinib Boosts Hair Regrowth in Adolescents With Severe Alopecia Areata
March 14th 2025The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and eyelashes in adolescents with severe alopecia areata after 36 weeks, with faster response rates compared to adults.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
